Nama's AI scorecard currently rates Royalty Pharma Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is RPRX's P/E ratio?

Royalty Pharma trades at a trailing price-to-earnings ratio of 12.7.

When does RPRX report earnings?

Royalty Pharma's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $1.52.

What is the RPRX price target?

The median analyst price target from 8 analysts is $71.00, with a range of $61.00 – $78.00.

Is RPRX Shariah compliant?

Nama's AAOIFI-style screen reads Royalty Pharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does RPRX pay a dividend?

Yes — Royalty Pharma's dividend yield is 1.4%.

Nama Insights

Royalty Pharma (RPRX)

Healthcare · Biotechnology · NASDAQ

Royalty Pharma (RPRX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $38.70B, a trailing price-to-earnings ratio of 12.7 and a free-cash-flow yield of 5.0%. Over the most recent reported fiscal year, revenue grew 5.1% and free cash flow per share fell 4.0%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 6.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +39.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-3.5%

How far the last close sits under the highest price of the past five years.

Market cap	$38.70B
Trailing P/E	12.7
Price / book	4.4
Price / sales	15.3
FCF yield	5.0%
Dividend yield	1.4%
Gross margin	95.8%
Operating margin	19.8%
Net margin	32.0%
Revenue growth (YoY)	+5.1%
Revenue growth (3-yr annual)	+2.1%
EPS growth (YoY)	+17.2%
FCF/share growth (YoY)	-4.0%
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

RPRX earnings

Next report: Feb 10, 2027 (Q4 2026, EPS estimate $1.52). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	$1.21	$1.18	+2.5%	$690.10M
Q2 2026	Aug 5, 2026	$1.32	$1.27	+3.9%	$674.14M
Q1 2026	May 6, 2026	$1.30	$1.18	+10.2%	$630.58M
Q4 2025	Feb 11, 2026	$1.47	$1.33	+10.5%	$621.99M

RPRX analyst price target

Median target $71.00 from 8 analysts, ranging $61.00 – $78.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
GMAB	Genmab A/S	$32.98B	38.9
ROIV	Roivant Sciences	$28.08B	—

Explore live RPRX data on Nama Insights →

RPRX FAQ

Is RPRX a buy?: Nama's AI scorecard currently rates Royalty Pharma Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is RPRX's P/E ratio?: Royalty Pharma trades at a trailing price-to-earnings ratio of 12.7.
When does RPRX report earnings?: Royalty Pharma's next scheduled report is on Feb 10, 2027. Analysts expect EPS of $1.52.
What is the RPRX price target?: The median analyst price target from 8 analysts is $71.00, with a range of $61.00 – $78.00.
Is RPRX Shariah compliant?: Nama's AAOIFI-style screen reads Royalty Pharma as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does RPRX pay a dividend?: Yes — Royalty Pharma's dividend yield is 1.4%.